COMBINATION OF HMG-COA REDUCTASE INHIBITORS ATORVASTATIN OR SIMVASTATIN WITH A PHOSPHODIESTERASE 4 INHIBITOR, SUCH AS ROFLUMILAST FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES
The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof.Farmaceutska kompozicija koja sadrži farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, količinu inhibitora HMG-CoA reduktaze i najmanje jednu farmaceutski prihvatljivu pomoćnu supstancu, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so, i pri čemu prva količina i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja.Prijava sadrži još 55 patentnih zahteva.
